Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

Nature Medicine

Volumn 14, Issue 7, 2008, Pages 762-766

  Shen, Lin ^a   Peterson, Susan ^a   Sedaghat, Ahmad R ^a   McMahon, Moira A ^a   Callender, Marc ^a   Zhang, Haili ^a   Zhou, Yan ^a   Pitt, Eleanor ^a   Anderson, Karen S ^b   Acosta, Edward P ^c   Siliciano, Robert F ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; ETRAVIRINE; INTEGRASE INHIBITOR; L 240; L 525; L 870812; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; T 1249; TIPRANAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MEASUREMENT; PRIORITY JOURNAL; VIREMIA; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; INTEGRASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 46049096485     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1777     Document Type: Article

References (29)

1. Gulick, R.M. et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734-739 (1997).
2. Hammer, S.M. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337, 725-733 (1997).
3. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
4. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
5. Preston, B.D., Poiesz, B.J. & Loeb, L.A. Fidelity of HIV-1 reverse transcriptase. Science 242, 1168-1171 (1988).
6. Roberts, J.D., Bebenek, K. & Kunkel, T.A. The accuracy of reverse transcriptase from HIV-1. Science 242, 1171-1173 (1988).
7. Larder, B.A., Darby, G. & Richman, D.D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734 (1989).
8. Coffin, J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489 (1995).
9. Chou, T.C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 59, 253-276 (1976).
10. Chou, T.C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
11. Hill, A.V. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol. (Lond.) 40, iv-vii (1910).
12. Hoefnagel, J.G., Koopmans, P.P., Burger, D.M., Schuurman, R. & Galama, J.M. Role of the inhibitory quotient in HIV therapy. Antivir. Ther. 10, 879-892 (2005).
13. Morse, G.D., Catanzaro, L.M. & Acosta, E.P. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect. Dis. 6, 215-225 (2006).
14. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo http:// aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (2008).
15. Zhang, H. et al. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J. Virol. 78, 1718-1729 (2004).
16. McMahon, M.A. et al. The HBV drug entecavir-effects on HIV-1 replication and resistance. N. Engl. J. Med. 356, 2614-2621 (2007).
17. Ferguson, N.M., Fraser, C. & Anderson, R.M. Viral dynamics and anti-viral pharmacodynamics: rethinking in vitro measures of drug potency. Trends Pharmacol. Sci. 22, 97-100 (2001).
18. Acosta, E.P., Gerber, J.G. & Kuritzkes, D.R. in Antiretroviral Pharmacokinetics, Resistance Testing and Therapeutic Drug Monitoring (eds. Libman, H. & Makadon, H.J.) 115-136 (American College of Physicians Therapy Series: HIV, Philadelphia, 2007).
19. Bartlett, J.G. & Gallant, J.E. in 2007 Medical Management of HIV Infection 510 (Johns Hopkins Medicine Health Publishing Business Group, Baltimore, MD, 2007).
20. Madruga, J.V. et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase 3 trial. Lancet 370, 49-58 (2007).
21. Clotet, B. et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369, 1169-1178 (2007).
22. Ortiz, R. et al. Efficacy and safety of once-daily darunavir-ritonavir versus lopinavir-ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS (in the press).
23. Sedaghat, A.R., Dinoso, J.B., Shen, L., Wilke, C.O. & Siliciano, R.F. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc. Natl. Acad. Sci. USA 105, 4832-4837 (2008).
24. Weiss, J.N. The Hill equation revisited: uses and misuses. FASEB J. 11, 835-841 (1997).
25. Hoffman, A. & Goldberg, A. The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: pharmacodynamic implications. J. Pharmacokinet. Biopharm. 22, 449-468 (1994).
26. Ambrose, Z., Julias, J.G., Boyer, P.L., Kewalramani, V.N. & Hughes, S.H. The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine. J. Virol. 80, 2578-2581 (2006).
27. Pommier, Y., Johnson, A.A. & Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4, 236-248 (2005).
28. Pandey, K.K. et al. Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J. Virol. 81, 12189-12199 (2007).
29. Talal, A.H. et al. Pharmacodynamics of PEG-IFN-a differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43, 943-953 (2006).